Easy & risky trade Price target as shown on the graph Loss is 5% Gain is 40% and above Does it worth a try! Think about it and trade safe
$PFE Lepas Calls 70 Jun 16th 2023 Returns +10,125% $BNTX and $PFE Leaps The FDA approval of Pfizer’s COVID-19 vaccine is a ‘critical step forward in vaccine confidence’: Doctor Army gives Pfizer $3.5B contract to make 500 million COVID vaccine doses Pfizer authorizes $1 billion for oral COVID-19 treatment, CEO says Pfizer now expects its Covid vaccine to generate...
It appears as though CRSP is potentially bottoming out and forming an Ascending Triangle pattern. On the DMI there's been a bullish twist where I have placed the blue downward pointing finger. On the KST there's been a bullish cross where I have placed the blue check mark and upon back-testing the red line we've seen a bullish bounce where another check mark.
Likely around a 40% upside potential, Take profit around 1.4$ Blue line is normal trendline support Red line is Log chart support Take profit is 0.5 - 0.618 Fib of previous bounce
I'll just say that there are a lot of stocks and cryptos reaching breaking points, and they will most likely all do the same thing. I'm seeing plenty of potential for most everything to break to the downside but the bullish charts look strong so that's what I'm going with. This SESN chart looks really good, but it's at the tipping point as we speak.
Big Rock Partners Acquisition Corp. Announces Merger with NeuroRx, Inc. Combined Company to Have an Estimated Post-Transaction Equity Value in Excess Of $500 Million (Excluding Potential Earnout Payments), Assuming A Share Price Of At Least $10.00 Per Share NeuroRx, Inc. is a clinical stage, small molecule pharmaceutical company which develops novel therapeutics...
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures Cyclacel Pharmaceuticals has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. - Strategic investment from single biotech-focused institutional investor - - Enables...
For those looking to diversify their portfolio or a long-term investment. Here I bring you an option in the biotech sector: Bluebird Bio INC, the leader in targeted cell therapy. This stock is in an important support area. It is a zone where buyers will seek to accumulate to buy cheap. the risk in this operation is low compared to the profit potential
Fib levels are acting as strong support and resistance, is likely to start going down the fib ladder like a basketball. Also we have a trendline resistance from the last few weeks.
Key Takeaways A descending triangle is a signal for traders to take a short position to accelerate a breakdown. A descending triangle is detectable by drawing trend lines for the highs and lows on a chart. A descending triangle is the counterpart of an ascending triangle, which is another trend line based chart pattern used by technical analysts. Bullish flag...
BIOS BUY ENTRY 1 $3.18 ORDER FOR MARKET OPENING Entry 2 $2.98 Tp.1 $4.00 Tp.2 $6.00 Tp.3 $9.00 Tp.4 $11.50
BIOS looks to potentially be in a bullish cup and handle pattern that could potential send the stock to $6.
Maybe a bull flag or ascending triangle as well. It looks like they're trading above the 200 Day MA, which is bullish for the stock in determining the direction of the trend at times.
Since July 2017, every time CRSP has traded on or below the Green upward sloping trendline CRSP has seen some parabolic action. Time will tell per usual.
Very undervalued stock. 52 Week High was $46.00 52 Week Low was $3.22 Revenue for the 4th quarter of 2018 was $35.5 million, an 739% increase year over year. Total revenue for the year is $96.4 million. Could do 2x-3x from this level. Key data presentations at ECCMID 2019 include: Integrated Symposium Presentations •“Update on acute bacterial skin and skin...
Bio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in...
$CRBP BIO STOCK >200 MA Break @ 7.08 > Median Analyst Target 26+ Chart is setting up with the 200 MA break for a early set up to the Golden Cross, as the 50 MA is edging up. The stock will Blue Sky with a 11 break. Most Analysts have a target over 26 +. Fundamental Catalysts With Data coming and potential approvals could be " the excuse" to what the chart is...